---
type: CKG Bundle
title: GLP-1 Obesity
tags: [Healthcare & Life Sci]
timestamp: 2026-06-18T00:00:00Z
ckg:
  id: glp1-obesity
  nodes: 130
  license: CC BY 4.0
---

# GLP-1 Obesity — Compressed Knowledge Graph

```csv
ConceptID,ConceptLabel,TaxonomyID
1,Incretin hormones,FOUND
2,Glucagon-Like Peptide-1 (GLP-1),FOUND
3,Glucose-dependent Insulinotropic Polypeptide (GI,FOUND
4,GLP-1 receptor,FOUND
5,GIP receptor,FOUND
6,Dipeptidyl peptidase-4 (DPP-4),FOUND
7,Insulin secretion,FOUND
8,Glucagon suppression,FOUND
9,Gastric emptying delay,FOUND
10,Hypothalamic satiety signaling,FOUND
11,Beta cell function,FOUND
12,Adipose tissue biology,FOUND
13,Energy homeostasis,FOUND
14,Obesity pathophysiology,PATH
15,Body Mass Index (BMI),PATH
16,Visceral adiposity,PATH
17,Metabolic syndrome,PATH
18,Insulin resistance,PATH
19,Type 2 diabetes mellitus (T2DM),PATH
20,Dyslipidemia,PATH
21,Hypertension,PATH
22,Non-alcoholic fatty liver disease (NAFLD/MASH),PATH
23,Chronic kidney disease (CKD),PATH
24,Cardiovascular disease risk,PATH
25,Sarcopenic obesity,PATH
26,GLP-1 receptor agonist (GLP-1RA) drug class,DRUG
27,Liraglutide (Victoza / Saxenda),DRUG
28,Semaglutide (Ozempic / Wegovy),DRUG
29,Dulaglutide (Trulicity),DRUG
30,Exenatide (Byetta / Bydureon),DRUG
31,Tirzepatide (Mounjaro / Zepbound),DRUG
32,Oral semaglutide (Rybelsus 14mg),DRUG
33,Dose escalation protocol,DRUG
34,Subcutaneous injection formulation,DRUG
35,Half-life and dosing interval,DRUG
36,Once-weekly administration,DRUG
37,Dual GIP/GLP-1 agonism,DRUG
38,Triple agonism (GLP-1/GIP/glucagon),DRUG
39,Small molecule oral GLP-1 receptor agonists,DRUG
40,Weight loss efficacy endpoints,TRIAL
41,HbA1c reduction endpoints,TRIAL
42,SUSTAIN trial program (semaglutide T2DM),TRIAL
43,STEP trial program (semaglutide obesity),TRIAL
44,SURMOUNT trial program (tirzepatide obesity),TRIAL
45,SELECT trial (semaglutide cardiovascular outcome,TRIAL
46,LEADER trial (liraglutide cardiovascular),TRIAL
47,SCALE trial program (liraglutide obesity),TRIAL
48,AWARD trial program (dulaglutide),TRIAL
49,Cardiovascular outcome trial (CVOT) design,TRIAL
50,Major adverse cardiovascular events (MACE),TRIAL
51,Renal composite endpoints,TRIAL
52,Body composition measurement,TRIAL
53,Lean mass preservation endpoints,TRIAL
54,Gastrointestinal adverse events,COMPL
55,Nausea and vomiting management,COMPL
56,Pancreatitis risk,COMPL
57,Thyroid C-cell tumor risk,COMPL
58,Gallbladder disease,COMPL
59,Injection site reactions,COMPL
60,Hypoglycemia risk,COMPL
61,Weight regain after discontinuation,COMPL
62,Muscle wasting with GLP-1 therapy,COMPL
63,Polycystic ovary syndrome (PCOS),SPEC
64,Pediatric/adolescent obesity,SPEC
65,Psychiatric comorbidities and obesity,SPEC
66,Post-bariatric surgery weight regain,SPEC
67,Prader-Willi syndrome,SPEC
68,Hypothalamic obesity,SPEC
69,HIV-associated lipohypertrophy,SPEC
70,Cystic fibrosis-related diabetes,SPEC
71,Idiopathic intracranial hypertension,SPEC
72,Kidney transplant candidacy,SPEC
73,Atrial fibrillation,SPEC
74,Heart failure with preserved ejection fraction (,SPEC
75,Obstructive sleep apnea (OSA),SPEC
76,Major depressive disorder with obesity,SPEC
77,Alcohol use disorder,SPEC
78,Bariatric surgery (reference comparator),SPEC
79,Bariatric surgery vs GLP-1RA comparison,SPEC
80,Combination therapy strategies,COMBO
81,GLP-1RA plus enobosarm (SARM),COMBO
82,GLP-1RA plus behavioral lifestyle program,COMBO
83,GLP-1RA plus exercise intervention,COMBO
84,GLP-1RA plus metformin,COMBO
85,GLP-1RA plus bariatric surgery,COMBO
86,GLP-1RA discontinuation and maintenance protocol,COMBO
87,Real-world effectiveness vs trial efficacy,COMBO
88,Cost-effectiveness of GLP-1RA therapy,COMBO
89,Access and affordability barriers,COMBO
90,Pipeline agents overview,PIPELINE
91,Retatrutide (GLP-1/GIP/glucagon triple agonist),PIPELINE
92,TRIUMPH trial program (retatrutide),PIPELINE
93,CagriSema (cagrilintide plus semaglutide),PIPELINE
94,REDEFINE trial program (CagriSema),PIPELINE
95,Amycretin (amylin-GLP-1 dual agonist),PIPELINE
96,Amylin receptor signaling,FOUND
97,Amycretin mechanism,PIPELINE
98,Oral semaglutide 50mg formulation,PIPELINE
99,GLP-1 biosimilars,PIPELINE
100,SURMOUNT-5 head-to-head trial (tirzepatide vs se,TRIAL
101,SURMOUNT-5 primary outcome 72-week weight loss,TRIAL
102,Tirzepatide superior weight loss vs semaglutide,TRIAL
103,STEP-HFpEF trial (semaglutide in heart failure),TRIAL
104,STEP-HFpEF outcomes Kansas City Cardiomyopathy S,TRIAL
105,SELECT trial 20 percent MACE reduction non-diabe,TRIAL
106,SELECT cardiovascular benefit mechanism,TRIAL
107,FLOW trial (semaglutide in chronic kidney diseas,TRIAL
108,FLOW trial renal and cardiovascular endpoints,TRIAL
109,SURMOUNT-OSA trial (tirzepatide in sleep apnea),TRIAL
110,Zepbound FDA approval for moderate-severe OSA 20,APPROVAL
111,Wegovy FDA approval for cardiovascular risk redu,APPROVAL
112,Wegovy pediatric approval ages 12 plus,APPROVAL
113,Tirzepatide 22 percent average weight loss SURMO,TRIAL
114,GLP-1 neurological mechanisms,NEURO
115,GLP-1 receptor expression in brain regions,NEURO
116,Reward pathway modulation by GLP-1,NEURO
117,GLP-1 signal in alcohol and substance use disord,NEURO
118,GLP-1 signal in compulsive behavior reduction,NEURO
119,EVOKE trial (semaglutide in early Alzheimer dise,NEURO
120,Neuroinflammation and obesity,NEURO
121,GLP-1 neuroprotective hypothesis,NEURO
122,Muscle mass monitoring during GLP-1 therapy,MGMT
123,Protein intake recommendation during GLP-1 thera,MGMT
124,Resistance training with GLP-1 therapy,MGMT
125,Individualized dose maintenance strategy,MGMT
126,Shared decision making obesity treatment,MGMT
127,Supply shortage and formulary access issues,ACCESS
128,Compounded semaglutide controversy,ACCESS
129,Prior authorization burden GLP-1,ACCESS
130,Employer coverage expansion GLP-1,ACCESS
```

## Edges (prerequisite -> concept)
1 -> 2
1 -> 3
2 -> 4
3 -> 5
2 -> 6
2 -> 7
4 -> 7
2 -> 8
4 -> 8
2 -> 9
4 -> 9
2 -> 10
4 -> 10
7 -> 11
10 -> 13
12 -> 13
12 -> 14
13 -> 14
14 -> 15
14 -> 16
14 -> 17
16 -> 17
14 -> 18
17 -> 18
18 -> 19
11 -> 19
17 -> 20
17 -> 21
16 -> 22
18 -> 22
19 -> 23
21 -> 23
17 -> 24
19 -> 24
20 -> 24
21 -> 24
14 -> 25
15 -> 25
4 -> 26
2 -> 26
26 -> 27
26 -> 28
26 -> 29
26 -> 30
4 -> 31
5 -> 31
26 -> 31
28 -> 32
26 -> 33
26 -> 34
26 -> 35
28 -> 36
29 -> 36
31 -> 36
35 -> 36
31 -> 37
4 -> 37
5 -> 37
37 -> 38
26 -> 39
15 -> 40
26 -> 40
19 -> 41
26 -> 41
28 -> 42
41 -> 42
28 -> 43
40 -> 43
31 -> 44
40 -> 44
28 -> 45
24 -> 45
40 -> 45
27 -> 46
24 -> 46
41 -> 46
27 -> 47
40 -> 47
29 -> 48
41 -> 48
24 -> 49
40 -> 49
41 -> 49
49 -> 50
23 -> 51
49 -> 51
25 -> 52
40 -> 52
25 -> 53
52 -> 53
9 -> 54
26 -> 54
54 -> 55
26 -> 56
26 -> 57
26 -> 58
9 -> 58
34 -> 59
7 -> 60
26 -> 60
43 -> 61
44 -> 61
26 -> 61
25 -> 62
61 -> 62
14 -> 63
18 -> 63
14 -> 64
15 -> 64
14 -> 65
14 -> 66
40 -> 66
64 -> 67
10 -> 68
64 -> 68
16 -> 69
19 -> 70
14 -> 71
23 -> 72
24 -> 73
24 -> 74
14 -> 75
16 -> 75
65 -> 76
65 -> 77
14 -> 78
40 -> 78
78 -> 79
43 -> 79
44 -> 79
26 -> 80
62 -> 81
53 -> 81
80 -> 81
80 -> 82
40 -> 82
80 -> 83
52 -> 83
53 -> 83
80 -> 84
26 -> 84
79 -> 85
80 -> 85
61 -> 86
80 -> 86
43 -> 87
44 -> 87
47 -> 87
26 -> 88
40 -> 88
88 -> 89
38 -> 90
39 -> 90
38 -> 91
91 -> 92
40 -> 92
28 -> 93
93 -> 94
40 -> 94
26 -> 95
10 -> 96
95 -> 97
96 -> 97
2 -> 97
32 -> 98
28 -> 98
26 -> 99
31 -> 100
28 -> 100
44 -> 100
43 -> 100
100 -> 101
40 -> 101
100 -> 102
101 -> 102
28 -> 103
74 -> 103
40 -> 103
103 -> 104
74 -> 104
45 -> 105
50 -> 105
45 -> 106
105 -> 106
24 -> 106
28 -> 107
23 -> 107
51 -> 107
107 -> 108
51 -> 108
50 -> 108
31 -> 109
75 -> 109
44 -> 109
31 -> 110
75 -> 110
109 -> 110
28 -> 111
45 -> 111
105 -> 111
28 -> 112
64 -> 112
44 -> 113
40 -> 113
2 -> 114
4 -> 114
10 -> 114
114 -> 115
4 -> 115
115 -> 116
77 -> 116
77 -> 117
116 -> 117
116 -> 118
65 -> 118
28 -> 119
114 -> 119
114 -> 120
65 -> 120
114 -> 121
120 -> 121
119 -> 121
62 -> 122
53 -> 122
83 -> 122
62 -> 123
122 -> 123
83 -> 124
122 -> 124
33 -> 125
86 -> 125
26 -> 126
78 -> 126
82 -> 126
89 -> 127
99 -> 127
99 -> 128
89 -> 128
89 -> 129
21 -> 129
89 -> 130
88 -> 130

*Free CKG · Graphify.md · `pip install ckg-mcp` for all · own the knowledge layer, rent the model*